Akoya Biosciences, Inc. (AKYA) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 117 transactions totaling $15.9M, demonstrating a bullish sentiment with $10.1M in net insider flow. The most recent transaction on Jul 8, 2025 involved a transaction of 20,000 shares valued at $0.
No significant insider buying has been recorded for AKYA in the recent period.
No significant insider selling has been recorded for AKYA in the recent period.
Based on recent SEC filings, insider sentiment for AKYA is bullish with an Insider Alignment Score of 82/100 and a net flow of $10.1M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Akoya Biosciences, Inc. (AKYA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading AKYA stock, having executed 117 transactions in the past 90 days. The most active insider is Thomas A. Raffin (Executive), who has made 6 transactions totaling $10.1M.
Get notified when executives and directors at AKYA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jul 8, 2025 | Myla Lai Goldman | Executive | Other | 20,000 | $N/A | $0 | |
| Jul 8, 2025 | A. Raffin Thomas | Executive | Other | 234,592 | $N/A | $0 | |
| Jul 8, 2025 | A. Raffin Thomas | Executive | Other | 1,737,712 | $N/A | $0 | |
| Jul 8, 2025 | A. Raffin Thomas | Executive | Other | 15,937,535 | $N/A | $0 | |
| Jul 8, 2025 | Winkler Matthew | Executive | Other | 984,513 | $N/A | $0 | |
| Jul 8, 2025 | Bamford Pascal | Executive | Other | 9,488 | $N/A | $0 | |
| Jul 8, 2025 | Bamford Pascal | Executive | Other | 196,250 | $N/A | $0 | |
| Jul 8, 2025 | Frederick Ek John | Executive | Other | 193,750 | $N/A | $0 | |
| Jul 8, 2025 | Frederick Ek John | Executive | Other | 20,000 | $N/A | $0 | |
| Jul 8, 2025 | Frederick Ek John | Executive | Other | 54,452 | $N/A | $0 | |
| Jul 8, 2025 | Kamocsay Jennifer | Executive | Other | 16,772 | $N/A | $0 | |
| Jul 8, 2025 | Kamocsay Jennifer | Executive | Other | 162,500 | $N/A | $0 | |
| Jul 8, 2025 | Mckelligon Brian | Executive | Other | 947,688 | $N/A | $0 | |
| Jul 8, 2025 | Mckelligon Brian | Executive | Payment | 196,866 | $N/A | $0 | |
| Jul 8, 2025 | Mckelligon Brian | Executive | Other | 393,338 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 15 | $13.0M | 78.8% |
Sale(S) | 29 | $2.9M | 17.5% |
Payment(F) | 15 | $362.8K | 2.2% |
Exercise(M) | 17 | $243.4K | 1.5% |
Other(J) | 19 | $0 | 0.0% |
Award(A) | 20 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Insiders at Akoya Biosciences, Inc. are accumulating shares at an accelerated pace. With 16 insiders making 117 transactions totaling $13.0M in purchases versus $2.9M in sales, the net buying activity of $10.1M signals strong executive confidence. Thomas A. Raffin (Executive) leads the buying activity with $10.1M in transactions across all time.